Alira Health’s CDD Supports TVM Capital Healthcare Investment in DEBx Medical
We are pleased to have been an advisor on TVM Capital Healthcare’s investment in DEBx Medical. Following Alira Health’s Commercial Due Diligence (CDD), TVM Capital Healthcare, a global specialist healthcare private equity firm headquartered in Dubai and Singapore, has completed a multi-million euro investment in DEBx Medical, an Amsterdam-based medical devices company.
The investment will accelerate the introduction of the DEBx Medical solution, DEBRICHEM®, an innovative product for treating non-healing chronic wounds that is easy to use and highly effective in removing biofilm and curing hard-to-heal wounds. Chronic wounds pose a significant healthcare challenge, have the potential for poor patient health and quality of life outcomes, represent a substantial cost to healthcare systems, and are particularly pronounced in the Gulf Cooperation Council (GCC) countries, where high levels of diabetes contribute to the problem. As part of the firm’s investment, DEBx Medical will establish a regional headquarter and a production base in the Middle East and North Africa area (MENA).
“We are very pleased that the investment by TVM Capital Healthcare will enable DEBx Medical to commence commercialization of its groundbreaking product for the benefit of patients,” said Dr. Michal Raciborski, Managing Partner Financial Sponsors at Alira Health. “DEBx Medical has already successfully treated over 5,000 patients, and is about to introduce its product to the market.”
“With this investment from our TVM Healthcare Afiyah Fund, we will accelerate the market introduction of a product which will transform the management of chronic wounds, and improve the life of millions of patients,” Tristan de Boysson, Managing Partner of TVM Capital Healthcare, commented. “This investment is also part of our Fund’s strategy of bringing innovative, best-in-class healthcare solutions to the wider MENA region. We are looking forward to working together with the DEBx Medical management team.”
“We founded the company with the aim of innovating wound care, a market that has not seen significant innovation in a very long time,” Bert Quint, Co-founder and CEO of DEBx Medical, added. “Our product, DEBRICHEM®, has the potential to disrupt the chronic wound care market and help patients to heal fast, safely and effectively. After just one single treatment, more than 90% of chronic wounds start healing. TVM Capital Healthcare’s investment is testament to our technology, and we are looking forward to bringing our product to market together.”
For more information on Alira Health’s commercial due diligence and other consulting and clinical services enabled by technology and real-world evidence, visit AliraHealth.com.